Galera Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.galeratx.com
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05412472
- Locations
- 🇺🇸
Inventiv Health Clinical -Research Pharmacy Unit, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
- Conditions
- SBRTBorderline Resectable Pancreatic CancerUnresectable Pancreatic Cancer
- Interventions
- Drug: Drug GC4711Drug: Placebo
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT04698915
- Locations
- 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04555096
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Mercy Research, Saint Louis, Missouri, United States
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
- Conditions
- Head and Neck CancerOral Mucositis
- Interventions
- Radiation: Intensity-modulated radiation therapy (IMRT)
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04529850
- Locations
- 🇵🇱
Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland
🇩🇪Universitatsklinikum Leipzig AoR, Leipzig, Germany
🇧🇪Onze-Lieve-Vrouwziekenhuis (OLVZ) - Campus Aalst, Aalst, Belgium
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
- Conditions
- SBRTNSCLCNon-metastatic
- Interventions
- Drug: Placebo +SBRTDrug: GC4711 +SBRT
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04476797
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Parkland Health and Hospital System, Dallas, Texas, United States
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
- Conditions
- Esophagitis
- Interventions
- Drug: GC4419 (avasopasem manganese)
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04225026
- Locations
- 🇺🇸
Cancer Care St. Joseph/Mosaic Life Care, Saint Joseph, Missouri, United States
🇺🇸IACT Health, Columbus, Georgia, United States
🇺🇸St. Francis Hospital, Greenville, South Carolina, United States
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03792971
- Locations
- 🇺🇸
Inventiv Health Clinical - Research Pharmacy Unit, Miami, Florida, United States
A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: GC4711 30mgDrug: GC4711 120mgDrug: GC4711 90mgDrug: PlaceboDrug: GC4711 60mgDrug: GC4711 75mgDrug: GC4711 105mg
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03762031
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
- Conditions
- Oral Mucositis
- Interventions
- Drug: GC4419 90mgDrug: Placebo
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 455
- Registration Number
- NCT03689712
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Oncology- Dallas Presbyterian Hospital, Dallas, Texas, United States
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
- Conditions
- Stereotactic Body Radiation TherapyPancreatic Cancer
- Interventions
- Drug: PlaceboRadiation: Stereotactic Radiation Therapy (SBRT) 50 GyRadiation: Stereotactic Radiation Therapy (SBRT) 55 Gy
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Galera Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03340974
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States